Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

Nasdaq-100 Stock Index / Technical Analysis

<ul>
<li>We remain bullish (as of our 4/21/26 Compass) on the S&amp;P 500 (SPX), and we will stay that way as long as support at 7507-7580 holds.</li>
<li>We also remain bullish on Technology and A.I. areas (XLK, SOXX, DRAM), and we have Technology on watch for a potential upgrade to overweight.</li>
<li>The Nasdaq 100 (QQQ) and the XLK are both breaking out of their 4-month bases, a very bullish sign as long as $745 and $197 supports hold on any pullbacks.</li>
</ul>


We remain bullish (as of our 4/21/26 Compass) on the S&amp;P 500 (SPX), and we will stay that way as long as support at 7507-7580 holds.
We also remain bullish on Technology and A.I. areas (XLK, SOXX, DRAM), and we have Technology on watch for a potential upgrade to overweight.
The Nasdaq 100 (QQQ) and the XLK are both breaking out of their 4-month bases, a very bullish sign as long as $745 and $197 supports hold on any pullbacks.


Nasdaq 100 and Technology (XLK) With 4-Month Base Breakouts; Downgrading Staples to Underweight

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

Aerovate Therapeutics  / Equity Bottom-Up

<ul>
  <li>
<a href="https://smartkarma.com/entities/aerovate-therapeutics-inc">Aerovate Therapeutics </a>has fundamentally pivoted its strategy following the clinical failure of its sole asset, AV-101, for Pulmonary Arterial Hypertension (PAH) in mid-2024.</li>
  <li>The company has since executed a reverse merger with Jade Biosciences, a private biotechnology firm focused on developing therapies for autoimmune diseases. The combined entity now operates as Jade Biosciences (trading under the ticker JBIO).</li>
  <li>The investment thesis is no longer based on Aerovate's original cardiopulmonary focus but on the potential of Jade's preclinical and clinical pipeline, primarily its lead candidate JADE-001 for IgA nephropathy, backed by a substantial concurrent financing.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
Aerovate Therapeutics has fundamentally pivoted its strategy following the clinical failure of its sole asset, AV-101, for Pulmonary Arterial Hypertension (PAH) in mid-2024.
  The company has since executed a reverse merger with Jade Biosciences, a private biotechnology firm focused on developing therapies for autoimmune diseases. The combined entity now operates as Jade Biosciences (trading under the ticker JBIO).
  The investment thesis is no longer based on Aerovate's original cardiopulmonary focus but on the potential of Jade's preclinical and clinical pipeline, primarily its lead candidate JADE-001 for IgA nephropathy, backed by a substantial concurrent financing.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Aerovate Therapeutics  (AVTE US) - Aug 2026

Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Thematic (Sector/Industry)

<ul><li>We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.</li><li>Last week, NVO had all semaglutide dosages listed available on the FDA drug shortage list, pressuring compounded GLP-1 seller HIMS.</li><li>ABBV acquired a private Alzheimer’s biotech, boosting neuro developers PRTA, VIGL, and ALEC.</li></ul>

We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&amp;A.Last week, NVO had all semaglutide dosages listed available on the FDA drug shortage list, pressuring compounded GLP-1 seller HIMS.ABBV acquired a private Alzheimer’s biotech, boosting neuro developers PRTA, VIGL, and ALEC.

Biopharma Week in Review - November 4, 2024

United States

Aerovate Therapeutics Inc. operates as a biotechnology company. The Company focuses on developing drugs that improve the lives of patients with cardiopulmonary disease. Aerovate Therapeutics serves medical industry in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Aerovate Therapeutics (AVTE US)

Nasdaq 100 and Technology (XLK) With 4-Month Base Breakouts; Downgrading Staples to Underweight

Nasdaq 100 $QQQ and Technology $XLK With 4-Month Base Breakouts; That is bullish as long as supports of $745 on QQQ and $197 on XLK hold on any...

Vermilion Research

Primer: Aerovate Therapeutics (AVTE US) - Aug 2026

Aerovate Therapeutics has fundamentally pivoted its strategy following the clinical failure of its sole asset, AV-101, for Pulmonary Arterial...

αSK Primers

Biopharma Week in Review - November 4, 2024

Last week, NVO had all semaglutide dosages listed available on the FDA drug shortage list, pressuring compounded GLP-1 seller HIMS.

Water Tower Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)